The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
In collaboration with the Soham Foundation, the initiative focused on perimenopause, menopause, and hormone replacement therapy awareness at BESCOM’s Bengaluru headquarters.
Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care
The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The facility combines advanced diagnostics, bone marrow transplant evaluation, prenatal awareness, and multidisciplinary support services
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
Approval strengthens the company’s growing international anti-infective portfolio
Subscribe To Our Newsletter & Stay Updated
